Navigation Links
Intrexon Organizes Around New Synthetic Biology Markets
Date:5/9/2013

GERMANTOWN, Md., May 9, 2013 /PRNewswire/ -- Intrexon Corporation, a leader in synthetic biology that is helping companies design and develop products incorporating its Better DNA™, today announced it has aligned its industry markets to focus on four key sectors: Health, Food, Energy and Environment.

Intrexon currently has nine collaborations in Health and Food to create products embodying engineered bio-based solutions.  The goal of the new market alignment is to accelerate business development across all of Intrexon's key market sectors using the company's Exclusive Channel Collaboration (ECC) model.

Since Intrexon's founding in 1998 the company has developed its core technology, the UltraVector® platform, to accelerate development of genetically-enhanced products at industrial scale.  Using a dynamic library of more than two million diverse, modular genetic components, UltraVector enables the discovery, design, assembly and testing of a wide spectrum of multigenic biological systems.As part of its new market strategy, Intrexon named the following executives with deep industry experience to lead each market sector:

  • Health will be led by Dr. Samuel Broder , Executive Director of the Intrexon Institute for Biomolecular Research and former Director of the National Cancer Institute.
  • Food will be led by Dr. Thomas Kasser , with more than twenty-five years of senior management experience in agricultural biotechnology and animal health and nutrition, recognized as a Monsanto Fellow for his scientific and technical excellence.
  • Energy will be led by Robert Walsh , with over 30 years of global petroleum and chemical industry experience, including 26 years at Royal Dutch Shell.
  • Environment will be led by Nick Macris , with 15 years in the specialty chemical, water treatment, agricultural chemical and biopesticide industries with many large and small companies including 3M, Rohm and Haas, and FMC Corporation
  • Chairman and Chief Executive Officer Randal J. Kirk said the new market alignment will help Intrexon achieve its vision to be one of the leading life science companies in the world.

    "Our new sector organization, led by an outstanding team of industry veterans, will bring additional focus and rapidity to solving our partners' toughest synthetic biology problems," Kirk said.  "It's a very exciting step toward empowering the bioindustrial revolution with solutions that enhance the quality and diversity of life."

    About Intrexon CorporationIntrexon Corporation is a privately held biotechnology company focused on collaborating with companies in Health, Food, Energy and the Environment to create bio-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform, Intrexon provides its partners with industrial-scale design and development of multigenic biology.  UltraVector delivers unprecedented control over the quality, reliability, and performance of living cells.  We call it Better DNA™ and we invite you to discover more at www.dna.com.

    TrademarksIntrexon, UltraVector, mAbLogix and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

    Safe Harbor StatementSome of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

    For more information regarding Intrexon Corporation, contact:Corporate Contact:Investor Contact:Marie L. Rossi, Ph.D.The Ruth GroupManager, Technical Communications

    Intrexon Corporation

    Tel: +1 301-556-9944

    mrossi@intrexon.com

     Stephanie Carrington / Melanie Sollid-Penton

    Tel: +1 646-536-7017/7009

    scarrington@theruthgroup.com

    msollid@theruthgroup.com 

     


    '/>"/>
    SOURCE Intrexon Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
    2. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
    3. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
    4. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
    5. The Spring 2012 MediSend Biomedical Repair Training Program™ Sends Graduating Biomedical Technicians to Hospitals Around the World
    6. Physicists in Mainz and all around the world cheer the discovery of the Higgs particle
    7. BioInformatics LLC New Product Launch – RateMyProduct, a Quick Turnaround Product Assessment Tool for Life Science Suppliers
    8. Reliable electric power supply for the energy turn-around
    9. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
    10. Synthetic Biology: Emerging Global Markets
    11. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
    (Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness Center ... the needs of consumers who are incorporating medical marijuana into their wellness and ... , As operators of two successful Valley dispensaries, The Giving Tree’s two founders, ...
    (Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
    (Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, ... webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured ... event is free and open to the public, but registration is required. , ...
    Breaking Biology Technology:
    (Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
    (Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
    (Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
    Breaking Biology News(10 mins):